Clinical trials: in Peru
HIV Infections
Long-term Follow-up of Long-acting Cabotegravir (CAB LA) for PrEP (Pre-exposure Prophylaxis) in Participants at Risk of Acquiring HIV (Human Immunodeficiency Virus)
The purpose of this study is long-term evaluation of long-acting injectable cabotegravir (CAB LA) for HIV pre-exposure prophylaxis (PrEP) in eligible participants who have completed DAIDS (Division of AIDS) sponsored studies HPTN…
- Trial name
- PALISADE (NCT06134362)
- Testing
- CAB LA
- Where
- 33 sites in Argentina, Botswana and 10 more
- Volunteers
- 2,998 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Papillomavirus Infections
Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)
The purpose of this study is to evaluate the efficacy, immunogenicity and safety of the 9vHPV vaccine in men 20 to 45 years of age.
- Trial name
- NCT04199689
- Testing
- 9vHPV Vaccine
- Where
- 103 sites in United States, Belgium and 14 more
- Volunteers
- 6,033 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Pre-Exposure Prophylaxis of HIV Infection
Pre-Exposure Prophylaxis Study of Lenacapavir in Cisgender Men, Transgender Women, Transgender Men, and Gender Nonbinary People at Risk for HIV Infection
The goal of this study is to evaluate the efficacy of the study drugs, lenacapavir (LEN) in preventing HIV infection, in participants ≥ 16 years of age who have condomless receptive anal sex with partners assigned male at birth…
- Trial name
- PURPOSE 2 (NCT04925752)
- Testing
- Oral Lenacapavir (LEN), F/TDF, Sub-cutaneous (SC) Lenacapavir (LEN)
- Where
- 93 sites in United States, Argentina and 6 more
- Volunteers
- 3,292 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis
A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)
Researchers are looking for new medicines to prevent HIV-1 (Human Immunodeficiency Virus Type 1) infection. The goals of this study are to learn: If taking MK-8527 once a month works to prevent HIV-1 infection as well as or…
- Trial name
- NCT07044297
- Testing
- MK-8527, FTC/TDF
- Where
- 81 sites in United States, Argentina and 14 more
- Volunteers
- 4,390 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HIV Preexposure Prophylaxis
Oral Islatravir (MK-8591) Once-Monthly as Preexposure Prophylaxis (PrEP) in Men and Transgender Women Who Are at High Risk for HIV-1 Infection (MK-8591-024)
The main purpose of the study is to evaluate the safety and tolerability of oral Islatravir (ISL) once monthly (QM) as Preexposure Prophylaxis (PrEP) in cisgender men who have sex with men (MSM) and transgender women (TGW) who…
- Trial name
- Impower-024 (NCT04652700)
- Testing
- ISL, FTC/TDF, FTC/TAF
- Where
- 25 sites in United States, Brazil and 5 more
- Volunteers
- 494 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Respiratory Syncytial Virus Infection
Efficacy and Safety of Clesrovimab (MK-1654) in Infants (MK-1654-004)
The primary objectives of this phase 2b/3 double-blind, randomized, placebo-controlled study are to evaluate the efficacy and safety of clesrovimab in healthy pre-term and full-term infants.
- Trial name
- CLEVER (NCT04767373)
- Testing
- Clesrovimab
- Where
- 217 sites in United States, Argentina and 22 more
- Volunteers
- 3,632 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Infertility of Uterine Origin, Implantation Failure
International Non-selection Study for ERA® Test in Patients With Previous Implantation Failures
Women´s period comprises different hormonal stages, being one of them the stage for maximum receptivity and proper embryo implantation.
- Trial name
- NCT06097559
- Testing
- Endometrial fluid and biopsy collection
- Where
- 8 sites in Argentina, Panama and 2 more
- Volunteers
- 738 people, healthy volunteers welcome
- Sponsor
- Igenomix
Dengue
A Study of JNJ-64281802 for the Prevention of Dengue Infection
The purpose of this study is to evaluate the prophylactic effect of JNJ-64281802 with respect to the prevention of laboratory-confirmed dengue virus (DENV) infection up to the last day of dosing among participants who have no…
- Trial name
- NCT05201794
- Testing
- JNJ-64281802
- Where
- 38 sites in Brazil, Colombia and 7 more
- Volunteers
- 1,595 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Gastroenteritis
Efficacy and Safety of Two Doses of HIL-214 in Children
This is a randomized, placebo-controlled study that is being done to evaluate the safety and effectiveness of two doses of the HIL-214 vaccine compared to a placebo.
- Trial name
- NCT05281094
- Testing
- HIL-214
- Where
- 17 sites in United States, Colombia and 5 more
- Volunteers
- 3,084 people, healthy volunteers welcome
- Sponsor
- HilleVax
Heart Murmurs, Wheezing
Validate the Efficacy and the Safety of the Keikku Electronic Stethoscope for Its Indication and Intended Purpose, Under the Intended Conditions of Use.
This study is testing a digital stethoscope called the Keikku electronic stethoscope. Doctors use stethoscopes to listen to the heart, and this new device records heart sounds using a smartphone app.
- Trial name
- KCI-1 (NCT07044128)
- Testing
- Digital stethoscope using MEMS sensor and mobile application for cardiac auscultation
- Where
- Peru
- Volunteers
- 149 people, healthy volunteers welcome
- Sponsor
- Lapsi Health Holding B.V.
Sunburn, Sun Damaged Skin
Natural Sunlight Protection and Simulated Sunlight Protection Offered by Sunscreens and Fabrics
The purpose of this study is to assess how human skin reacts and how sunscreens and sun protection fabrics protect in natural sunlight compared to their labeled claims, indoor testing methods (existing or modified) and…
- Conditions
- Sunburn, Sun Damaged Skin, Overexposure to Sun Rays
- Trial name
- NCT03007589
- Testing
- otc sunscreens, sun protection fabrics, Optical Filters
- Where
- 5 sites in United States, Chile and 1 more
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Sun Protection Foundation
Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19 at Different Stages of the Protocol
A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants
The study will evaluate the efficacy of Ad26.COV2.S in the prevention of molecularly confirmed moderate to severe/critical COVID-19, as compared to placebo, in adult participants.
- Trial name
- ENSEMBLE (NCT04505722)
- Testing
- Ad26.COV2.S
- Where
- 225 sites in United States, Argentina and 6 more
- Volunteers
- 44,325 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
Hematological Malignancy
Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies
Primary Objective: Phase 1: To determine the maximum tolerated dose (MTD)/maximum administered dose (MAD) of SAR650984 (Isatuximab).
- Trial name
- NCT01084252
- Testing
- Isatuximab SAR650984, Dexamethasone
- Where
- 59 sites in United States, Argentina and 15 more
- Volunteers
- 351 people, healthy volunteers welcome
- Sponsor
- Sanofi
Coronavirus Disease (COVID-19)
Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013)
The purpose of the study is to assess if the study medication (molnupiravir, MK-4482) will prevent symptomatic coronavirus disease 2019 (COVID-19) in adults who live with someone with confirmed COVID-19 infection.
- Trial name
- MOVe-AHEAD (NCT04939428)
- Testing
- Molnupiravir
- Where
- 226 sites in United States, Argentina and 21 more
- Volunteers
- 2,441 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Healthy
A Study of Heterologous Vaccine Regimen of Adenovirus Serotype 26 Mosaic4 Human Immunodeficiency Virus(Ad26.Mos4.HIV), Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 Infection Among Cis-gender Men and Transgender Individuals Who Have Sex With Cis-gender Men and/or Transgender Individuals
The purpose of this study is to evaluate the vaccine efficacy (VE) of a heterologous vaccine regimen utilizing Ad26.Mos4.HIV and aluminum phosphate-adjuvanted Clade C gp140 and Mosaic gp140 for the prevention of HIV-1 infection…
- Trial name
- MOSAICO (NCT03964415)
- Testing
- Ad26.Mos4.HIV, Clade C and Mosaic gp140 HIV bivalent vaccine
- Where
- 53 sites in United States, Argentina and 7 more
- Volunteers
- 3,900 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
Contraception
Efficacy and Safety of Etonogestrel + 17β-Estradiol Vaginal Ring and Levonorgestrel-Ethinyl Estradiol Combined Oral Contraceptive in Adult Women at Risk for Pregnancy (MK-8342B-062)
The purpose of this study is to assess the contraceptive efficacy of the etonogestrel + 17β-estradiol (ENG-E2) vaginal ring in women between 18 and 35 years of age based on the number of in-treatment pregnancies as expressed by…
- Trial name
- NCT02616146
- Testing
- ENG-E2 125 μg/300 μg vaginal ring, LNG-EE 150 μg/30 μg COC
- Where
- 14 sites in Austria, Costa Rica and 12 more
- Volunteers
- 2,016 people, healthy volunteers welcome
- Sponsor
- Organon and Co
Covid19, SARS-CoV-2
A Phase 2b/3, Randomized, Observer-Blinded, Placebo-Controlled, Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and Older
The primary objective of the randomized observer-blinded phase 2b/3 part of this trial is to demonstrate the efficacy of a 2-dose schedule of CVnCoV in the prevention of first episodes of virologically-confirmed cases of COVID-19…
- Trial name
- NCT04652102
- Testing
- CVnCoV, Authorized/licensed vaccines for preventing COVID-19 (AV) as standard of care through their national vaccination program
- Where
- 46 sites in Argentina, Belgium and 8 more
- Volunteers
- 39,680 people, healthy volunteers welcome
- Sponsor
- CureVac
COVID-19, SARS-CoV-2
Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults
The aim of the study is to assess the safety, efficacy, and immunogenicity of AZD1222 for the prevention of COVID-19.
- Trial name
- NCT04516746
- Testing
- AZD1222
- Where
- 84 sites in United States, Chile and 1 more
- Volunteers
- 32,450 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Coronavirus, Covid19
A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19
This study aims to evaluate the safety and reactogenicity profile after 1 and 2 dose administrations of investigational SARS-CoV-2 mRNA vaccine (CVnCoV) at different dose levels and to evaluate the humoral immune response after 1…
- Conditions
- Coronavirus, Covid19, SARS-CoV-2, Severe Acute Respiratory Syndrome
- Trial name
- NCT04515147
- Testing
- CVnCoV 6 μg, CVnCoV 12 μg, Hepatitis A vaccine
- Where
- 2 sites in Panama, Peru
- Volunteers
- 668 people, healthy volunteers welcome
- Sponsor
- CureVac
Pneumococcal Infections
A Study to Evaluate the Safety and Tolerability of V114 and Prevnar 13™ in Healthy Infants (V114-031/PNEU-LINK)
This study is designed to evaluate the safety and tolerability of V114 and Prevnar 13™ in healthy infants. This study will include both full-term infants (≥37 weeks gestational age) and premature infants (<37 weeks gestational…
- Trial name
- NCT03692871
- Testing
- V114, Prevnar 13™
- Where
- 76 sites in United States, Australia and 8 more
- Volunteers
- 2,409 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC